AI Article Synopsis

  • Diabetes mellitus increases the risk of target lesion failure (TLF) after coronary interventions, prompting a study on 5-year outcomes of biodegradable polymer stents in diabetic patients.
  • The SORT OUT VII trial compared the effectiveness of two different stents (O-SES and N-BES) in over 2,500 patients, focusing on TLF and other heart-related issues over five years.
  • Results showed that diabetic patients had higher TLF and patient-related complications compared to non-diabetics, but no significant differences in TLF rates between the two stent types among diabetic patients.

Article Abstract

Background: Diabetes mellitus is associated with higher risk of target lesion failure (TLF) after percutaneous coronary intervention. We studied the 5-year outcome in patients with diabetes mellitus treated with biodegradable polymer stents.

Methods: The SORT OUT VII was a randomised trial comparing the ultrathin sirolimus-eluting Orsiro stent (O-SES) and the biolimus-eluting Nobori stent (N-BES) in an all-comer setting. Patients ( = 2525) were randomised to receive O-SES ( = 1261, diabetes: = 236) or N-BES ( = 1264, diabetes: = 235). Endpoints were TLF (a composite of cardiac death, target-lesion myocardial infarction (MI), target lesion revascularization (TLR)), definite stent thrombosis and a patient related outcome (all-cause mortality, MI and revascularization) within 5 years.

Results: Patients with diabetes mellitus had higher TLF (20.6% vs 11.0%, (Rate ratio (RR) 1.85 95% confidence interval (CI): (1.42-2.40) and patient related outcome (42.0% vs 31.0%, RR 1.43 95% CI: (1.19-1.71)) compared to patients without diabetes. Among patients with diabetes mellitus, TLF after 5 years did not differ between O-SES and N-BES (21.2% vs 20.0%), RR 1.05 95% CI: (0.70-1.58), = 0.81). Cardiac death, MI, TLR, and definite stent thrombosis did not differ between the groups.

Conclusion: In patients with diabetes mellitus, 5-year outcomes were similar among patients treated with biodegradable polymer O-SES or N-BES.

Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01879358.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450620PMC
http://dx.doi.org/10.1177/14791641241283939DOI Listing

Publication Analysis

Top Keywords

patients diabetes
24
diabetes mellitus
24
biodegradable polymer
12
diabetes
9
patients
8
outcomes patients
8
mellitus treated
8
sort vii
8
target lesion
8
treated biodegradable
8

Similar Publications

Alström syndrome: the journey to diagnosis.

Orphanet J Rare Dis

January 2025

Department of Diabetes, Endocrinology and Metabolism, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK.

Background: Alström syndrome (AS) is a recessively inherited genetic condition which is ultra-rare and extremely complex. Symptoms include retinal dystrophy, nystagmus, photophobia, hearing loss, obesity, insulin resistance, diabetes and cardiomyopathy. The condition is progressive, but it is important to note that not all the complications associated with AS occur in everyone affected.

View Article and Find Full Text PDF

Pre-pregnancy BMI modifies the associations between triglyceride-glucose index in early pregnancy and adverse perinatal outcomes: a 5-year cohort study of 67,936 women in China.

Diabetol Metab Syndr

January 2025

The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, No. 910, Hengshan Rd., Shanghai, 200030, China.

Background: Triglyceride-glucose (TyG) index was suggested as a possible surrogate for insulin resistance and a predictor for cardiovascular diseases and diabetes in the non-pregnant population. However, the relationship between TyG index in early pregnancy and adverse pregnancy outcomes (APOs), and the contribution of pre-pregnancy body mass index (BMI) was still illusive.

Methods: A large retrospective cohort study involving 67,936 pregnant Chinese women between 2017 and 2022 was conducted.

View Article and Find Full Text PDF

Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.

View Article and Find Full Text PDF

Background: We sought to determine how the COVID-19 pandemic affected care delivery for HIV patients in Ghana.

Methods: Guided by the Consolidated Framework for Implementation Research (CFIR), we performed a cross-sectional study between May and July 2021 among 40 people living with HIV and 19 healthcare providers caring for HIV patients. In-depth interviews and focus group discussions were done with HIV patients, doctors, nurses, pharmacists, laboratory scientists, data scientists, administrators, and counselors to ascertain barriers and facilitators to HIV care during the pandemic.

View Article and Find Full Text PDF

Metabolic syndrome index measurement tool (MSI): scale development, reliability and validity study.

BMC Public Health

January 2025

Vocational School of Health Services, Medical Services and Techniques Department, First and Emergency Aid Programme, Bayburt University, Bayburt, 69000, Turkey.

Aim: Identifying the risks of metabolic syndrome (MetS) can lead to early targeted interventions and thus contribute to improved quality of life by reducing the risk of developing MetS, diabetes or heart disease in the future. We aimed to develop a valid and reliable measurement tool to measure the MetS risk of the population.

Materials And Methods: In the methodological study, an item pool was created by reviewing the literature.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!